Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1172/JCI145516 http://scihub22266oqcxt.onion/10.1172/JCI145516 33571162!8011891!33571162     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Clin+Invest 2021 ; 131 (7): ä Nephropedia Template TP {{tp|p=33571162|t=2021. Durable SARS-CoV-2 B cell immunity after mild or severe disease |pdf=|usr=}}{{33571162}} gab.com Text Durable SARS-CoV-2 B cell immunity after mild or severe disease JO: J Clin Invest http://www.kidney.de/pget.php?&tw=1&pmid=33571162 #FOAvip Multiple studies have shown loss of severe acute respiratory syndrome coronavirus 2-specific (SARS-CoV-2-specific) antibodies over time after infection, raising concern that humoral immunity against the virus is not durable. If immunity wanes quickly, millions of people may be at risk for reinfection after recovery from coronavirus disease 2019 (COVID-19). However, memory B cells (MBCs) could provide durable humoral immunity even if serum neutralizing antibody titers decline. We performed multidimensional flow cytometric analysis of S protein receptor binding domain-specific (S-RBD-specific) MBCs in cohorts of ambulatory patients with COVID-19 with mild disease (n = 7), and hospitalized patients with moderate to severe disease (n = 7), at a median of 54 days (range, 39-104 days) after symptom onset. We detected S-RBD-specific class-switched MBCs in 13 of 14 participants, failing only in the individual with the lowest plasma levels of anti-S-RBD IgG and neutralizing antibodies. Resting MBCs (rMBCs) made up the largest proportion of S-RBD-specific MBCs in both cohorts. FCRL5, a marker of functional memory on rMBCs, was more dramatically upregulated on S-RBD-specific rMBCs after mild infection than after severe infection. These data indicate that most SARS-CoV-2-infected individuals develop S-RBD-specific, class-switched rMBCs that resemble germinal center-derived B cells induced by effective vaccination against other pathogens, providing evidence for durable B cell-mediated immunity against SARS-CoV-2 after mild or severe disease. Twit Text FOAVip Durable SARS-CoV-2 B cell immunity after mild or severe disease ????J Clin Invest http://www.kidney.de/pget.php?&tw=1&pmid=33571162 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33571162 #FOAvip English Wikipedia <ref>{{Cite pmid|33571162}}</ref> Durable SARS-CoV-2 B cell immunity after mild or severe disease #MMPMID33571162 Ogega CO; Skinner NE; Blair PW; Park HS; Littlefield K; Ganesan A; Dhakal S; Ladiwala P; Antar AA; Ray SC; Betenbaugh MJ; Pekosz A; Klein SL; Manabe YC; Cox AL; Bailey JR J Clin Invest 2021[Apr]; 131 (7): ä PMID33571162show ga Multiple studies have shown loss of severe acute respiratory syndrome coronavirus 2-specific (SARS-CoV-2-specific) antibodies over time after infection, raising concern that humoral immunity against the virus is not durable. If immunity wanes quickly, millions of people may be at risk for reinfection after recovery from coronavirus disease 2019 (COVID-19). However, memory B cells (MBCs) could provide durable humoral immunity even if serum neutralizing antibody titers decline. We performed multidimensional flow cytometric analysis of S protein receptor binding domain-specific (S-RBD-specific) MBCs in cohorts of ambulatory patients with COVID-19 with mild disease (n = 7), and hospitalized patients with moderate to severe disease (n = 7), at a median of 54 days (range, 39-104 days) after symptom onset. We detected S-RBD-specific class-switched MBCs in 13 of 14 participants, failing only in the individual with the lowest plasma levels of anti-S-RBD IgG and neutralizing antibodies. Resting MBCs (rMBCs) made up the largest proportion of S-RBD-specific MBCs in both cohorts. FCRL5, a marker of functional memory on rMBCs, was more dramatically upregulated on S-RBD-specific rMBCs after mild infection than after severe infection. These data indicate that most SARS-CoV-2-infected individuals develop S-RBD-specific, class-switched rMBCs that resemble germinal center-derived B cells induced by effective vaccination against other pathogens, providing evidence for durable B cell-mediated immunity against SARS-CoV-2 after mild or severe disease. |*SARS-CoV-2/immunology[MESH] |Adult[MESH] |Aged[MESH] |Antibodies, Neutralizing/blood[MESH] |Antibodies, Viral/blood[MESH] |B-Lymphocytes/*immunology[MESH] |Binding Sites/immunology[MESH] |COVID-19/*immunology/virology[MESH] |Case-Control Studies[MESH] |Cohort Studies[MESH] |Female[MESH] |Humans[MESH] |Immunity, Cellular[MESH] |Immunoglobulin Class Switching[MESH] |Immunologic Memory[MESH] |Male[MESH] |Middle Aged[MESH] |Pandemics[MESH] |Severity of Illness Index[MESH] |Spike Glycoprotein, Coronavirus/chemistry/immunology[MESH]Durable SARS-CoV-2 B cell immunity after mild or severe disease (epmc).pdf DeepDyve Pubget Overpricing